Bioxytran (OTCMKTS:BIXT – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Bioxytran Stock Performance
BIXT stock opened at $0.02 on Friday. Bioxytran has a 52 week low of $0.02 and a 52 week high of $0.09. The firm’s fifty day moving average is $0.03 and its 200 day moving average is $0.03. The firm has a market cap of $2.41 million, a P/E ratio of -0.70 and a beta of 1.98.
Bioxytran Company Profile
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Featured Stories
- Five stocks we like better than Bioxytran
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
